Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Arq. bras. oftalmol ; 87(4): e2022, 2024.
Article in English | LILACS-Express | LILACS | ID: biblio-1520239

ABSTRACT

ABSTRACT Purpose: Opsoclonus-myoclonus syndrome is extremely uncommon in adults with an autoimmune pathophysiology. Because of the rarity of the syndrome, international recognition of opsoclonus-myoclonus-ataxia syndrome needs to be improved urgently. Therefore, the goal of this study was to raise the awareness of the opsoclonus-myoclonus-ataxia syndrome and help doctors in better diagnosing and using immunotherapy. Methods: We present a case study of an adult-onset case of idiopathic opsoclonus-myoclonus syndrome characterized by spontaneous arrhythmic multidirectional conjugate eye movements, myoclonus, ataxia, sleep disorders, and intense fear. Additionally, we conduct a literature search and summarize the pathophysiology, clinical presentation, diagnosis, and treatment of opsoclonus-myoclonus-ataxia syndrome. Results: Immunotherapies successfully treated the patient's opsoclonus, myoclonus, and ataxia. Further, the article also includes an update summary of the opsoclonus-myoclonus-ataxia syndrome. Conclusion: The prevalence of residual sequela in adults with opsoclonus-myoclonus-ataxia syndrome is low. Early diagnosis and treatment may result in a better prognosis. Furthermore, combined immunotherapy is expected to reduce the incidence of refractory and reoccurring opsoclonus-myoclonus-ataxia syndrome.


RESUMO Objetivo: A síndrome de opsoclonia-mioclonia é extremamente rara em adultos e tem uma fisiopatologia autoimune. Devido à raridade dessa síndrome, o reconhecimento da síndrome de opsoclonia-mioclonia-ataxia precisa melhorar urgentemente em todo o mundo. Assim sendo, este estudo visou aumentar a conscientização sobre a síndrome de opsoclonia-mioclonia-ataxia e ajudar os médicos para um melhor diagnóstico e o uso correto da imunoterapia. Métodos: Este é o relato de um caso adulto de síndrome de opsoclonia-mioclonia idiopática com movimentos oculares conjugados, multidirecionais, arrítmicos e espontâneos, mioclonia, ataxia, distúrbios do sono e medo intenso. Além disso, foram pesquisadas as publicações recentes relevantes e resumiu-se a fisiopatologia, a apresentação clínica, o diagnóstico e o tratamento da síndrome de opsoclonia-mioclonia-ataxia. Resultados: A paciente recuperou-se totalmente da opsoclonia, da mioclonia e da ataxia através de imunoterapia. O artigo também fornece um resumo atualizado sobre a síndrome de opsoclonia-mioclonia-ataxia. Conclusão: Adultos com síndrome de opsoclonia-mioclonia-ataxia têm uma baixa frequência de sequelas residuais. O diagnóstico e o tratamento precoces podem levar a melhores prognósticos. Espera-se que a imunoterapia combinada reduza a incidência da síndrome de opsoclonia-mioclonia-ataxia refratária e recorrente.

2.
Med. UIS ; 35(2): e502, mayo-ago. 2022. tab
Article in Spanish | LILACS | ID: biblio-1422051

ABSTRACT

Resumen El síndrome de opsoclonia mioclonía es una entidad neurológica poco frecuente que afecta a los niños en la etapa preescolar. Clínicamente se caracteriza por una triada clásica de opsoclonía, mioclonía y ataxia aguda, con una evolución progresiva o incluso de manera incompleta. Su etiología puede ser paraneoplásica, en la mayoría de los casos en asociación con neuroblastomas, así como postinfecciosa o parainfecciosa, autoinmune o idiopática. En objetivo del tratamiento es la inmunomodulación con terapia de primera línea con esteroides endovenosos aunque pudiendo asociarse a recaídas y secuelas a largo plazo en el ámbito neurológico y conductual. El síndrome de opsoclonia mioclonía representa un reto diagnóstico en los pacientes con ataxia aguda dada la variedad de presentación clínica, por tanto es importante tener una alta sospecha diagnostica para garantizar un tratamiento oportuno y evitar secuelas futuras.


Abstract Opsoclonus myoclonus syndrome is a rare neurological entity affecting preschool children. Clinically it is characterized by a classic triad of opsoclonus, myoclonus, and acute ataxia, with a progressive or even incomplete course. Its etiology can be paraneoplastic, in most cases in association with neuroblastomas, as well as postinfectious or parainfectious, autoimmune or idiopathic. The goal of treatment is immunomodulation with first-line therapy with intravenous steroids, although it can be associated with relapses and long-term neurological and behavioral sequelae. The opsoclonus myoclonus syndrome represents a diagnostic challenge in patients with acute ataxia given the variety of clinical presentations, therefore it is important to have a high diagnostic suspicion to ensure timely treatment and aoid future sequelae.


Subject(s)
Humans , Infant
3.
Chinese Journal of Neurology ; (12): 223-228, 2022.
Article in Chinese | WPRIM | ID: wpr-933785

ABSTRACT

Objective:To summarize the clinical features of childhood opsoclonus-myoclonus syndrome (OMS), evaluate severity degree and prognosis using OMS Symptom Severity Standard Rating Scale.Methods:The clinical features,diagnosis, therapeutic regimen and follow-up of 9 children with OMS in Department of Neurology and Oncology Department of Children's Hospital of Fudan University between 2011 and 2019 were retrospectively reviewed. Severity degree and prognosis were evaluated using OMS Symptom Severity Standard Rating Scale.Results:Among the 9 children with OMS, 4 were males and 5 were females. The onset age ranged from 14 months to 5 years, with a median of 17 months. Main symptoms were opsoclonus, myoclonus, ataxia, motor function regression, behavior and mood changes and sleep disorders. Eghit patients were combined with tumor. Seven of them with neuroblastoma were confirmed by surgical pathology, the other one showed spontaneous regression and symptom remission without treatment. Eight patients received hormone combined with intravenous immunoglobulin, of which 3 cases received adrenocorticotropic hormone, while 5 cases received methylprednisolone pulse therapy, with prednisone sequential therapy, decreasing dose gradually. Rituximab was administrated in 3 patients whose annual recurrent time was≥2. Nine patients were divided into 3 groups according to OMS Symptom Severity Standard Rating Scale, 1 of mild degree, 3 of moderate degree, 5 of severe degree. There was no recurrence and sequelae in the mild-degree patient after 3 years follow-up. There was no recurrence and sequelae in 2 of the moderate-degree patients after 1-2 years follow-up. Different degrees of motor, cognitive sequelae were found in 1 of moderate-degree patients and all of severe-degree patients after 1-8 years follow-up.Conclusions:Childhood OMS patients have early onset age. Bad symptom severity before treatment and multiphase course are associated with poor prognosis. OMS Symptom Severity Standard Rating Scale is suitable for estimations of long-term prognosis.

4.
Acta neurol. colomb ; 35(3)set. 2019.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1533482

ABSTRACT

El síndrome de Opsoclonus mioclonus ataxia (SOMA) es una entidad infrecuente en niños, caracterizada por Opsoclonus, mioclonías / ataxia y alteraciones de conducta o de sueño. En la actualidad representa una gran morbilidad dada su naturaleza paraneoplásica y autoinmune; destaca su asociación frecuente con tumores neuroblásticos y su tendencia hacia la cronicidad, recaídas y secuelas en el neurodesarrollo. Se revisa el caso de lactante de 13 meses, uno de los casos reportados a más temprana edad en Colombia, cuyo motivo de consulta fue irritabilidad, temblor distal, opsoclonía, con pruebas negativas para neuroinfección. Posteriormente a estudios se describieron dos masas en ápice torácico izquierdo, una de ellas entre carótida interna y yugular externa. La masa más grande fue de manejo quirúrgico; la patología reportó ganglioneuroblastoma de patrón nodular. No se logró resección quirúrgica completa y tuvo recaída de síntomas; como complicación posquirúrgica se presentó síndrome de Horner incompleto. Al tener difícil acceso quirúrgico se optó por manejo con poliquimioterapia protocolo de riesgo intermedio del COG (Children Oncology Group), que recibió por un año con resolución completa del cuadro clínico. Se presenta el caso de lactante con SOMA de difícil manejo, en el cual el abordaje quirúrgico falló y se requirió terapia complementaria. La quimioterapia se convierte en una opción de manejo cuando la resección quirúrgica no sea completa.


SUMMARY The opsoclonus myoclonus ataxia syndrome (OMA) is an infrequent entity in children, characterized opsoclonus, myoclonus/ataxia, sleep pattern or behavioral alterations. It represents great morbidity given its paraneoplastic and autoimmune nature; it is frequently associated with neuroblastic tumors and its tendency towards chronicity, relapses and neurodevelopmental sequels. We examine the case of a previously healthy thirteen months toddler, one of the earliest age reported cases in Colombia, who consulted for irritability, distal tremor, opsoclonus, and had negative neuroinfection tests. It was reported, after additional studies, the presence of 2 masses in the left pulmonary apex; one of them between the internal carotid artery and the external jugular vein. The bigger mass was surgically removed; pathology reported a ganglioneuroblastoma with nodular pattern. It was not possible to make full surgical resection and the patient experienced a relapse; as a postsurgical complication the patient had transient incomplete Horner syndrome. Due to difficult surgical access, chemotherapy was used for a whole year following the intermediate risk protocol developed by the COG (Children Oncology Group) with full resolution of the symptoms. We present the case of a toddler with difficult surgical approach where the surgical treatment failed, and complementary chemotherapy was needed. Chemotherapy turns into a therapeuthic option when surgical resection is not complete.

5.
Korean Journal of Otolaryngology - Head and Neck Surgery ; : 355-360, 2019.
Article in Korean | WPRIM | ID: wpr-760128

ABSTRACT

The dizziness associated with paraneoplastic neurologic syndrome is hard to diagnose clinically because the prevalence of disease is rare, and radiologic and serologic examination result may come out normal. Opsoclonus-myoclonus symdrome is a representative of classical paraneoplastic neurologic syndromes. In this paper, we report 2 cases of paraneoplastic neurologic syndromes with negative serologic auto-antibody test and no brain lesion on MRI. Both cases were eventually diagnosed through PET. Patients with opsoclonus-myoclonus type nystagmus should be evaluated for paraneoplastic neurologic syndrome even if their radiologic and serologic findings are normal.


Subject(s)
Humans , Brain , Dizziness , Magnetic Resonance Imaging , Myoclonus , Ocular Motility Disorders , Opsoclonus-Myoclonus Syndrome , Paraneoplastic Syndromes, Nervous System , Prevalence
6.
Journal of the Korean Balance Society ; : 34-37, 2017.
Article in Korean | WPRIM | ID: wpr-761229

ABSTRACT

Scrub typhus is an infective acute febrile disorder caused by the intracellular parasite Orientia tsutsugamushi. Neurological manifestations of scrub typhus are meningoencephalitis, cerebellitis, transverse myelitis, papilledema, and cranial nerve palsy. However, opsoclonus-myoclonus syndrome associated with scrub typhus has been rarely reported. A 59-year-old man developed vertigo, nausea, vomiting, and imbalance following scrub typhus infection for eight days. Examination showed eschar at the axilla, decreased mentality, and opsoclonus-myoclonus syndrome. Video-oculography disclosed opsoclonus with an amplitude of 15°–20° and a frequency of 6–8 Hz. The serum antibody titers to Orientia tsutsugamushi were 1:5,120, and cerebrospinal fluid analysis revealed pleocytosis. Brain magnetic resonance imaging was normal. Neurological symptoms and signs completely improved by systemic steroid and antibiotics treatment. Various mechanisms including direct disseminating inflammation or indirect immune modulation may give rise to neurological complications following scrub typhus.


Subject(s)
Humans , Middle Aged , Anti-Bacterial Agents , Axilla , Brain , Cerebrospinal Fluid , Cranial Nerve Diseases , Encephalitis , Inflammation , Leukocytosis , Magnetic Resonance Imaging , Meningoencephalitis , Myelitis, Transverse , Nausea , Neurologic Manifestations , Ocular Motility Disorders , Opsoclonus-Myoclonus Syndrome , Orientia tsutsugamushi , Papilledema , Parasites , Scrub Typhus , Vertigo , Vomiting
7.
Acta neurol. colomb ; 31(2): 209-213, abr.-jun. 2015. ilus, tab
Article in Spanish | LILACS | ID: biblio-949585

ABSTRACT

El síndrome opsoclonus mioclonus (SOM) es una entidad poco frecuente en pediatría que por consenso de expertos se define como aquel que cumple tres de cuatro criterios: opsoclonus, ataxia, mioclonus, alteraciones de la conducta o del sueño y diagnóstico de neuroblastoma. Frecuentemente el SOM en niños se presenta asociado a tumores de la cresta neural, siendo el neuroblastoma el más prevalente, seguido por ganglioneuroblastoma, ganglioneuroma y hepatoblastoma. La asociación SOM y neuroblastoma tiene su pico de incidencia entre los 6 y 36 meses de edad y la posibilidad de que un niño con SOM tenga un neuroblastoma es de cerca del 50%. Si bien el SOM no es una patología frecuente en pediatría, su asociación con enfermedades neoplásicas sí lo es y desconocer su existencia y la presentación clínica puede llevar a demoras o subdiagnóstico del tumor con impacto negativo en el pronóstico tanto de la entidad de base como del futuro neurológico del paciente. Se presenta el caso de una niña de 15 meses con SOM asociado a ganglioneuroblastoma retroperitoneal que mejoró luego de la resección del tumor y el tratamiento con corticoides e inmunoglobulina.


Opsoclonus Myoclonus Syndrome (OMS) is a rare condition in children, that for expert consensus is defined to be met three of the four criteria: opsoclonus, ataxia, myoclonus, behavioral disorders or sleep and diagnosis of neuroblastoma. OMS frequently occurs in children associated with neural crest tumors, the most prevalent being neuroblastoma, followed by ganglioneuroblastoma, ganglioneuroma, and hepatoblastoma. The OMS association and neuroblastoma has a peak incidence between 6 and 36 months of age and the possibility that a child with neuroblastoma have a OMS is about 50%. While the OMS is not a common pediatric pathology, its association with neoplastic disease is very strong and ignore its existence and clinical presentation may lead to delays or underdiagnosis of the tumor with negative impact on the prognosis of the entity base and the future neurological patient. Here we present the case of a girl of 15 months with OMS associated with retroperitoneal ganglioneuroblastoma that improved after tumor resection and treatment with corticosteroids and immunoglobulin.


Subject(s)
Child , Opsoclonus-Myoclonus Syndrome , Neuroblastoma
8.
Journal of the Korean Neurological Association ; : 103-105, 2015.
Article in Korean | WPRIM | ID: wpr-195249

ABSTRACT

Opsoclonus-myoclonus syndrome (OMS) is characterized by opsoclonus and arrhythmic myoclonic jerks predominantly involving the trunk, limbs, and head. We present two patients with OMS after respiratory tract infection who exhibited diffuse cerebral hypometabolism, particularly in the parieto-occipital cortex on 18F-fluorodeoxyglucose positron-emission tomography (F-FDG PET). This metabolic change might be a consequence rather than a direct cause of motor symptoms, which may be attributable to brainstem or cerebellar pathology.


Subject(s)
Humans , Brain Stem , Extremities , Head , Myoclonus , Ocular Motility Disorders , Opsoclonus-Myoclonus Syndrome , Pathology , Positron-Emission Tomography , Respiratory Tract Infections
9.
Rev. bras. anestesiol ; 63(3): 287-289, maio-jun. 2013.
Article in Portuguese | LILACS | ID: lil-675847

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: A síndrome de Kinsbourne é uma doença neurológica rara que afeta, principalmente, crianças previamente hígidas, na faixa etária entre seis e trinta e seis meses, caracterizada pela presença de opsoclonia (movimentos oculares rápidos, irregulares, horizontais e verticais), mioclonias que podem afetar tronco, extremidades ou face e ataxia cerebelar. Pode ser considerada uma síndrome paraneoplásica pela associação com neuroblastomas, ganglioneuroma e raramente hepatoblastomas. Foi objetivo deste artigo apresentar os aspectos mais relevantes da síndrome de Kinsbourne, bem como a técnica anestésica usada para ressecção de tumor de mediastino em uma criança portadora desta síndrome. RELATO DO CASO: Criança de um ano e cinco meses com diagnóstico de tumor do mediastino posterior portadora de síndrome de Kinsbourne. Pré-medicação com midazolam oral. Indução da anestesia com sevoflurano, óxido nitroso, fentanil e rocurônio. Manutenção da anestesia com sevoflurano, óxido nitroso, fentanil e rocurônio. Reversão do bloqueio neuromuscular com neostigmina associado à atropina. Analgesia pós-operatória com o uso de dipirona, cetoprofeno e morfina. Levada para a Unidade de Terapia Intensiva extubada, com parâmetros hemodinâmicos e respiratórios estáveis. Alta da UTI quatro dias após a cirurgia e alta hospitalar no sétimo dia de pós-operatório sem intercorrências. Anátomo-patológico evidenciou para ganglioneuroblastoma. CONCLUSÕES: A síndrome de Kinsbourne é uma doença neurológica rara. As drogas usadas em nosso paciente mostraram ser seguras e permitiram uma anestesia sem intercorrências. Drogas que desencadeiam ou agravam opsoclonia e mioclonias, como cetamina e etomidato, deverão ser evitadas nesses pacientes.


BACKGROUND AND OBJECTIVES: Kinsbourne syndrome is a rare neurological disorder that primarily affects children previously healthy and aged between 6 and 36 months. It is characterized by opsoclonus (rapid, irregular, horizontal and vertical eye movements) and myoclonus that may affect trunk, limbs or face, and cerebellar ataxia. It may be considered a paraneoplastic syndrome by association with neuroblastomas, hepatoblastomas and, rarely, ganglioneuromas. The aim of this paper was to present the most relevant aspects of Kinsbourne syndrome, as well as the technique used for resection of mediastinal tumor in a child with this syndrome. CASE REPORT: Child, 1 year and 5 months, with a diagnosis of posterior mediastinal tumor and Kinsbourne syndrome. Premedicated with oral midazolam. Anesthesia induced with sevoflurane, nitrous oxide, fentanyl, and rocuronium. Maintenance of anesthesia with sevoflurane, nitrous oxide, fentanyl, and rocuronium. Neuromuscular block reversal with neostigmine combined with atropine. Postoperative analgesia with the use of dipyrone, morphine, and ketoprofen. Taken to the intensive care unit extubated, with stable hemodynamic and respiratory parameters. ICU discharge four days after surgery and hospital discharged on the seventh postoperative day without complications. Anatomopathological examination revealed ganglioneuroblastoma. CONCLUSIONS: Kinsbourne syndrome is a rare neurological disorder. The drugs used in our patient proved safe and allowed an uneventful anesthesia. Drugs that trigger or aggravate opsoclonus and myoclonus, such as ketamine and etomidate, should be avoided in these patients.


JUSTIFICATIVA Y OBJETIVOS: El síndrome de Kinsbourne es una enfermedad neurológica rara que afecta principalmente a los niños anteriormente sanos, en una franja etaria entre los 6 y los 36 meses, y que se caracteriza por la presencia de opsoclonia (movimientos oculares rápidos, irregulares, horizontales y verticales), mioclonias que pueden afectar el tronco, las extremidades o la cara, y por la ataxia cerebelar. Puede ser considerado un síndrome paraneoplásico por la asociación con los neuroblastomas, ganglioneroma y raramente hepatoblastomas. El objetivo de este artículo, fue presentar los aspectos más relevantes del síndrome de Kinsbourne, como también la técnica anestésica usada para la resección del tumor del mediastino en un niño portador de ese síndrome. RELATO DEL CASO: Niño de 1 año y 5 meses con diagnóstico de tumor del mediastino posterior, portador del síndrome de Kinsbourne. Premedicación con midazolam oral. Inducción de la anestesia con sevoflurano, óxido nitroso, fentanilo y rocuronio. Mantenimiento de la anestesia con sevoflurano, óxido nitroso, fentanilo y rocuronio. Reversión del bloqueo neuromuscular con neostigmina asociado a la atropina. Analgesia postoperatoria con el uso de dipirona, cetoprofeno y morfina. Fue derivado a la Unidad de Cuidados Intensivos y desentubado con parámetros hemodinámicos y respiratorios estables. El alta de la UCI fue cuatro días después de la cirugía y el alta hospitalaria fue al séptimo día del postoperatorio sin intercurrencias. La anatomo-patología arrojó un ganglioneuroblastoma. CONCLUSIONES: El síndrome de Kinsbourne es una enfermedad neurológica rara. Los fármacos usados en nuestro paciente, mostraron ser seguros permitiendo una anestesia sin intercurrencias. Los fármacos que desencadenan o que agravan la opsoclonia y mioclonias, como la cetamina y el etomidato, deberán ser evitados en esos pacientes.


Subject(s)
Female , Humans , Infant , Anesthesia , Mediastinal Neoplasms/surgery , Opsoclonus-Myoclonus Syndrome , Anesthesia/methods , Mediastinal Neoplasms/complications , Opsoclonus-Myoclonus Syndrome/complications
10.
Arch. pediatr. Urug ; 84(3): 210-214, 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-754192

ABSTRACT

El síndrome de opsoclonus-mioclonus o síndrome de Kinsbourne es un trastorno poco frecuente. El diagnóstico es clínico y se caracteriza por la presencia de opsoclonus, mioclonías, ataxia, irritabilidad y trastornos del sueño. En 45% de los casos se asocia con la presencia de neuroblastoma. Es un trastorno de origen inmunitario y sutratamiento es en base a inmunosupresores, inmunomoduladores y resección tumoral en los casos secundarios a neuroblastoma. Durante años los corticoides han sido el tratamiento gold standard, asociándose posteriormente la inmunoglobulina endovenosa. Sinembargo, dada la alta prevalencia de corticodependencia y de sus efectos adversos, así como el mal pronóstico neurológico (entre 70% y 80% de los casos pueden tener secuelas neurológicas: déficit cognitivo, alteraciones visuales, motoras, práxicas, del lenguaje y conductuales), las investigaciones en los últimos años se han centrado en la utilización de nuevos fármacos. Los últimos estudios publicados avalan el uso de la terapia multimodal con el agregado de un tercer fármaco como el rituximab o laciclofosfamida. Se presenta el caso clínico de un varón de 2 años y 4 meses con diagnóstico de síndrome deopsoclonus-mioclonus se cundario a un neuroblastomatorácico en el que se realizó la resección tumoral y tratamiento con corticoides, inmunoglobulina y ciclofosfamida. Presentó una recaída frente al descenso de los corticoides y, actualmente, al año y seis meses del diagnóstico bajo dosis bajas de corticoides tiene un retraso en la adquisición del lenguaje sin otros síntomas acompañantes...


Subject(s)
Humans , Male , Child, Preschool , Neuroblastoma/complications , Opsoclonus-Myoclonus Syndrome/diagnosis , Opsoclonus-Myoclonus Syndrome/etiology , Opsoclonus-Myoclonus Syndrome/therapy , Thoracic Neoplasms , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use
11.
Journal of the Korean Society of Emergency Medicine ; : 510-512, 2010.
Article in Korean | WPRIM | ID: wpr-180110

ABSTRACT

Opsoclonus-myoclonus syndrome (OMS) is a rare neurologic disorder characterized by progressive opsoclonus (irregular, rapid, horizontal and vertical eye movements), myoclonus, cerebellar dysfunction and severe hypotonia. Here we present the case of a 19-year-old man with OMS induced by mumps virus infection. Emergency physicians should know about the typical presentation of OMS and make a proper response.


Subject(s)
Humans , Young Adult , Cerebellar Diseases , Emergencies , Eye , Mumps , Mumps virus , Muscle Hypotonia , Myoclonus , Nervous System Diseases , Ocular Motility Disorders , Opsoclonus-Myoclonus Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL